Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line

Varicellovirus bovinealpha (BoAHV) 1 and 5 activate distinct toll-like receptors signaling pathways in neural cells

Varicellovirus bovinealpha (BoAHV) types 5 and 1 are closely-related, neurotropic alphaherpesviruses. BoAHV-5 is the etiological agent of non-suppurative meningoencephalitis in calves, whereas BoAHV-1 is responsible for several syndromes in cattle, including respiratory and reproductive diseases. The innate immune response mediated by TLR3 and TLR7 is crucial in controlling infection and modulating pro-inflammatory cytokines, such as IFNs. In this study, it was evaluated whether TLR3 and TLR7 agonists affect BoAHV replication and whether TLR stimulation has an effect on the IFN-λ3 response in neural cells. TLR3 and TLR7 expression in neural cells was induced by the TLR agonists, Poly I:C and Imiquimod, respectively. The antiviral effect of the agonists varied with the virus strain. TLR7 was suppressed early after BoAHV-5 infection and it was upregulated during BoAHV-1 infection. Imiquimod pre-treatment of neural cells induced higher levels of TLR7 mRNA and reduced the replication of the natural BoAHV-5/1 recombinant. In this study, TLR3 expression was completely inhibited during infection with BoAHV-5 and there was a marked up-regulation of TLR3 mRNA during BoAHV-1 infection. Poly I:C treatment up-regulated TLR3 expression in infected cells but a detrimental effect on BoAHV-5 replication was not observed. Infection of neural cells with the recombinant virus A665 stimulated TLR3 expression late in the infectious cycle. Steady levels of BoAHV-1 replication were maintained in the presence of IFN-λ3 and this cytokine was unable to slow the replication of BoAHV-5. For BoAHV-5/1 A663 strain there was a consistent induction of IFN-λ3 throughout the infection period and maximum A663 titers at advanced stages of the replication cycle were in agreement with a decrease in expression levels. The study emphasizes the importance of strain-specific factors, the infection phase and the cell type involved in virus- and agonist-induced TLR and IFN-λ3 expression. Furthermore, these results evidenced that a deeper analysis on the role and activity of TLR agonists on BoAHV infection should be conducted to evaluate their potential as preventive or therapeutic molecules.

Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies

Hepatitis B virus (HBV) chronically infects over 250 million people worldwide and causes nearly 1 million deaths per year due to cirrhosis and liver cancer. Approved treatments for chronic infection include injectable type-I interferons and nucleos(t)ide reverse transcriptase inhibitors. A small minority of patients achieve seroclearance after treatment with type-I interferons, defined as sustained absence of detectable HBV DNA and surface antigen (HBsAg) antigenemia. However, type-I interferons cause significant side effects, are costly, must be administered for months, and most patients have viral rebound or non-response. Nucleos(t)ide reverse transcriptase inhibitors reduce HBV viral load and improve liver-related outcomes, but do not lower HBsAg levels or impart seroclearance. Thus, new therapeutics are urgently needed. Lambda interferons (IFNLs) have been tested as an alternative strategy to stimulate host antiviral pathways to treat HBV infection. IFNLs comprise an evolutionarily conserved innate immune pathway and have cell-type specific activity on hepatocytes, other epithelial cells found at mucosal surfaces, and some immune cells due to restricted cellular expression of the IFNL receptor. This article will review work that examined expression of IFNLs during acute and chronic HBV infection, the impact of IFNLs on HBV replication in vitro and in vivo, the association of polymorphisms in IFNL genes with clinical outcomes, and the therapeutic evaluation of IFNLs for the treatment of chronic HBV infection.

Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B

Infection with the hepatitis B virus (HBV) is still a major global health threat as 250 million people worldwide continue to be chronically infected with the virus. While patients may be treated with nucleoside/nucleotide analogues, this only suppresses HBV titre to sub-detection levels without eliminating the persistent HBV covalently closed circular DNA (cccDNA) genome. As a result, HBV infection cannot be cured, and the virus reactivates when conditions are favorable. Interferons (IFNs) are cytokines known to induce powerful antiviral mechanisms that clear viruses from infected cells. They have been shown to induce cccDNA clearance, but their use in the treatment of HBV infection is limited as HBV-targeting immune cells are exhausted and HBV has evolved multiple mechanisms to evade and suppress IFN signalling. Thus, to fully utilize IFN-mediated intracellular mechanisms to effectively eliminate HBV, instead of direct IFN administration, novel strategies to sustain IFN-mediated anti-cccDNA and antiviral mechanisms need to be developed. This review will consolidate what is known about how IFNs act to achieve its intracellular antiviral effects and highlight the critical interferon-stimulated gene targets and effector mechanisms with potent anti-cccDNA functions. These include cccDNA degradation by APOBECs and cccDNA silencing and transcription repression by epigenetic modifications. In addition, the mechanisms that HBV employs to disrupt IFN signalling will be discussed. Drugs that have been developed or are in the pipeline for components of the IFN signalling pathway and HBV targets that detract IFN signalling mechanisms will also be identified and discussed for utility in the treatment of HBV infections. Together, these will provide useful insights into design strategies that specifically target cccDNA for the eradication of HBV.

Improving therapeutic potential of non-viral minimized DNA vectors

The tragic deaths of three patients in a recent AAV-based X-linked myotubular myopathy clinical trial highlight once again the pressing need for safe and reliable gene delivery vectors. Non-viral minimized DNA vectors offer one possible way to meet this need. Recent pre-clinical results with minimized DNA vectors have yielded promising outcomes in cancer therapy, stem cell therapy, stem cell reprograming, and other uses. Broad clinical use of these vectors, however, remains to be realized. Further advances in vector design and production are ongoing. An intriguing and promising potential development results from manipulation of the specific shape of non-viral minimized DNA vectors. By improving cellular uptake and biodistribution specificity, this approach could impact gene therapy, DNA nanotechnology, and personalized medicine.

Correction to: Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line

Following publication of the original article [1], the authors reported an error that occurred during the production process.